Back to results
US 2014/0193406 A1Published application
Methods used in identifying glioblastoma
AssigneeThe Translational Genomics Research Institute
InventorNHAN TRAN
Life of this patent
Estimating the term…
Abstract
The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy.
Claims20
A method of treating a patient with cancer, the method comprising the steps of:
- sensitizing the patient to a treatment by reducing an expression level of a marker selected from the group consisting of SEQ ID NO. 3 and SEQ ID NO. 4;
- and
- administering a therapeutically effective amount of the treatment to the patient.
A method of characterizing a tumor as invasive and sensitizing the invasive tumor for treatment, the method comprising the steps of:
- adding a first reagent capable of binding to a marker selected from the group consisting of SEQ ID NO. 3 and SEQ ID NO. 4 to a mixture comprising a sample of the tumor;
- subjecting the mixture to conditions that allow detection of binding of the reagent to the marker;
- classifying the tumor as invasive when the binding of the reagent to the marker is increased compared to a control sample;
- and
- reducing an expression level of the marker to sensitize the invasive tumor to a treatment.
2 more elements
A method of characterizing a tumor as invasive and sensitizing the invasive tumor for treatment, the method comprising the steps of:
- receiving a sample from the tumor;
- adding a reagent capable of binding to a marker selected from the group consisting of SEQ ID NO. 3 and SEQ ID NO. 4 to a mixture comprising the sample;
- subjecting the mixture to conditions that allow detection of the binding of the reagent to the marker;
- classifying the tumor as an invasive when the binding of the reagent to the marker in the sample is more than twice the binding of the reagent to a control sample;
- and
- reducing an expression level of the marker to sensitize the invasive tumor to a treatment.
3 more elements
Dependencies are inferred from the claim text.